Tesofensine

Tesofensine (also known as NS2330) is a prominently researched experimental compound classified strictly within the Small Molecule framework. Operating primarily through advanced pharmacological pathways, it functions by triple monoamine reuptake inhibitor (inhibits reuptake of serotonin, noradrenaline, and dopamine). Originates as an Alzheimer's/Parkinson's drug but abandoned due to massive weight loss profiles. with a documented biological half-life of roughly 216 hours, in preclinical investigative trials and independent academic studies, researchers utilizing Tesofensine have documented significant, quantifiable biological outcomes, primarily focusing on extreme fat loss and appetite suppression without glp-1 side effects. Typical research protocols investigate administering 250 to 500mcg via oral pathways daily. However, it is critically important to understand that while Tesofensine demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.